Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Revolution Medicines (RVMD) EBITDA Margin: 2019-2025

Historic EBITDA Margin for Revolution Medicines (RVMD) over the last 5 years, with Sep 2025 value amounting to 2,654.81%.

  • Revolution Medicines' EBITDA Margin was N/A to 2,654.81% in Q3 2025 from the same period last year, while for Sep 2025 it was 9,413.49%, marking a year-over-year change of. This contributed to the annual value of 23,707.12% for FY2024, which is 2745533.00% up from last year.
  • As of Q3 2025, Revolution Medicines' EBITDA Margin stood at 2,654.81%, which was up 137.84% from -7,015.31% recorded in Q4 2024.
  • Revolution Medicines' 5-year EBITDA Margin high stood at 5,014.56% for Q1 2024, and its period low was -21,579.78% during Q4 2023.
  • Over the past 3 years, Revolution Medicines' median EBITDA Margin value was -1,958.32% (recorded in 2023), while the average stood at -4,140.39%.
  • In the last 5 years, Revolution Medicines' EBITDA Margin slumped by 2,117,726bps in 2023 and then soared by 1,456,448bps in 2024.
  • Revolution Medicines' EBITDA Margin (Quarterly) stood at -559.33% in 2021, then soared by 15,681bps to -402.52% in 2022, then tumbled by 2,117,726bps to -21,579.78% in 2023, then skyrocketed by 1,456,448bps to -7,015.31% in 2024, then reached 2,654.81% in 2025.
  • Its last three reported values are 2,654.81% in Q3 2025, -7,015.31% for Q4 2024, and 5,014.56% during Q1 2024.